EA201070327A1 - Катехоламиновые производные и их пролекарства - Google Patents

Катехоламиновые производные и их пролекарства

Info

Publication number
EA201070327A1
EA201070327A1 EA201070327A EA201070327A EA201070327A1 EA 201070327 A1 EA201070327 A1 EA 201070327A1 EA 201070327 A EA201070327 A EA 201070327A EA 201070327 A EA201070327 A EA 201070327A EA 201070327 A1 EA201070327 A1 EA 201070327A1
Authority
EA
Eurasian Patent Office
Prior art keywords
devices
catecholamine derivatives
catecholamine
derivatives
therapy
Prior art date
Application number
EA201070327A
Other languages
English (en)
Other versions
EA018413B1 (ru
Inventor
Мортен Йергенсен
Бенни Банг-Андерсен
Аск Пюшль
Нильс Мерк
Дженнифер Ларсен
Хокан Вильхельм Викстрем
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39877715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA201070327A1 publication Critical patent/EA201070327A1/ru
Publication of EA018413B1 publication Critical patent/EA018413B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

Настоящее изобретение относится к новым катехоламиновым производным формулы I, способам их получения, содержащим их фармацевтическим композициям и их применению в терапии.
EA201070327A 2007-08-31 2008-08-28 Фармацевтические композиции на основе катехоламиновых производных и их применение EA018413B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701250 2007-08-31
PCT/DK2008/050215 WO2009026935A1 (en) 2007-08-31 2008-08-28 Catecholamine derivatives and prodrugs thereof

Publications (2)

Publication Number Publication Date
EA201070327A1 true EA201070327A1 (ru) 2010-08-30
EA018413B1 EA018413B1 (ru) 2013-07-30

Family

ID=39877715

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200971107A EA018011B1 (ru) 2007-08-31 2008-08-28 Катехоламиновые производные, полезные для лечения болезни паркинсона
EA201070327A EA018413B1 (ru) 2007-08-31 2008-08-28 Фармацевтические композиции на основе катехоламиновых производных и их применение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200971107A EA018011B1 (ru) 2007-08-31 2008-08-28 Катехоламиновые производные, полезные для лечения болезни паркинсона

Country Status (29)

Country Link
EP (4) EP2197883B1 (ru)
JP (4) JP5548125B2 (ru)
KR (3) KR101597367B1 (ru)
CN (3) CN107253956A (ru)
AR (2) AR068045A1 (ru)
AU (2) AU2008291425B2 (ru)
BR (2) BRPI0813456A2 (ru)
CA (2) CA2691961C (ru)
CL (2) CL2008002558A1 (ru)
CO (2) CO6270232A2 (ru)
CY (1) CY1117326T1 (ru)
DK (1) DK2197883T3 (ru)
EA (2) EA018011B1 (ru)
ES (1) ES2557485T3 (ru)
HR (1) HRP20151334T1 (ru)
HU (1) HUE025882T2 (ru)
IL (1) IL203080A (ru)
MX (1) MX2010002210A (ru)
MY (2) MY179527A (ru)
NZ (2) NZ583551A (ru)
PL (1) PL2197883T3 (ru)
PT (1) PT2197883E (ru)
RS (1) RS54470B1 (ru)
SG (1) SG184711A1 (ru)
SI (1) SI2197883T1 (ru)
TW (2) TWI404702B (ru)
UA (2) UA97989C2 (ru)
WO (2) WO2009026935A1 (ru)
ZA (2) ZA200909191B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
EP2303851A1 (en) * 2008-06-27 2011-04-06 H. Lundbeck A/S Novel phenolic and catecholic amines and prodrugs thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
JP7320507B2 (ja) 2017-11-24 2023-08-03 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US11111263B2 (en) * 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) * 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US20220213040A1 (en) 2019-05-21 2022-07-07 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease
JP2022533913A (ja) * 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US20220220077A1 (en) * 2019-05-21 2022-07-14 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN113677675A (zh) * 2019-05-21 2021-11-19 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN114478298A (zh) * 2020-11-12 2022-05-13 成都西岭源药业有限公司 一种造影剂碘佛醇的纯化方法
CN116568672A (zh) 2020-11-17 2023-08-08 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN113620760A (zh) * 2021-09-07 2021-11-09 张家口思睿凯科技有限公司 一种电子盐反应液和不饱和芳香烃类化合物的还原方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
CH648300A5 (en) * 1979-06-22 1985-03-15 Sandoz Ag Phenanthrene derivatives and medicaments containing them
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
JPH03163078A (ja) * 1989-08-30 1991-07-15 Sankyo Co Ltd 光学活性な縮環複素環化合物及びその製法
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
EP0861234A1 (en) * 1995-11-10 1998-09-02 Novo Nordisk A/S Enantiomers of cis-benz e]indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
CN1241998A (zh) * 1996-10-30 2000-01-19 伊莱利利公司 苯并[f]喹啉酮的合成
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Also Published As

Publication number Publication date
NZ583551A (en) 2012-07-27
ZA200909191B (en) 2011-03-30
AR068044A1 (es) 2009-10-28
EP2195291A1 (en) 2010-06-16
WO2009026934A1 (en) 2009-03-05
TW200911752A (en) 2009-03-16
AU2008291425A1 (en) 2009-03-05
JP2010536889A (ja) 2010-12-02
CY1117326T1 (el) 2017-04-26
HRP20151334T1 (hr) 2016-01-01
EA018413B1 (ru) 2013-07-30
BRPI0813456A2 (pt) 2014-12-23
CN101842354A (zh) 2010-09-22
WO2009026935A1 (en) 2009-03-05
TW200914426A (en) 2009-04-01
AR068045A1 (es) 2009-10-28
SG184711A1 (en) 2012-10-30
UA97989C2 (ru) 2012-04-10
MY179527A (en) 2020-11-10
EA018011B1 (ru) 2013-04-30
CL2008002564A1 (es) 2009-07-17
CN101687878A (zh) 2010-03-31
SI2197883T1 (sl) 2016-01-29
DK2197883T3 (en) 2016-01-11
CL2008002558A1 (es) 2009-08-07
KR20100046111A (ko) 2010-05-06
EP2197883A1 (en) 2010-06-23
NZ582379A (en) 2011-08-26
JP5548125B2 (ja) 2014-07-16
CA2691961C (en) 2013-12-17
AU2008291426A1 (en) 2009-03-05
TWI404702B (zh) 2013-08-11
KR101597367B1 (ko) 2016-02-24
RS54470B1 (en) 2016-06-30
JP2014148528A (ja) 2014-08-21
JP5802792B2 (ja) 2015-11-04
KR20150115963A (ko) 2015-10-14
PL2197883T3 (pl) 2016-03-31
AU2008291426B2 (en) 2013-01-31
JP2010536890A (ja) 2010-12-02
ZA201001422B (en) 2011-06-29
EP3009437A1 (en) 2016-04-20
CA2691961A1 (en) 2009-03-05
CO6270232A2 (es) 2011-04-20
EP2197883B1 (en) 2015-11-18
KR20100051834A (ko) 2010-05-18
UA98804C2 (ru) 2012-06-25
EP2662358A1 (en) 2013-11-13
MY148948A (en) 2013-06-14
MX2010002210A (es) 2010-03-17
CN107253956A (zh) 2017-10-17
CA2697688A1 (en) 2009-03-05
IL203080A (en) 2014-11-30
BRPI0815894A2 (pt) 2015-02-24
AU2008291425B2 (en) 2012-12-06
EA200971107A1 (ru) 2010-06-30
ES2557485T3 (es) 2016-01-26
JP2014111635A (ja) 2014-06-19
CO6260082A2 (es) 2011-03-22
PT2197883E (pt) 2016-02-02
HUE025882T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201100030A1 (ru) Пиразольные соединения 436
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201170772A1 (ru) Органические соединения
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201100503A1 (ru) Глюкозидные производные и их применения
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA200970156A1 (ru) Пиридизиноновые производные
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201391644A1 (ru) Частично насыщенные трициклические соединения и способы их получения и применения
EA201492216A1 (ru) Ингибиторы бромодомена и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU